Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes

Authors: Marco Racioppi, Luca Di Gianfrancesco, Mauro Ragonese, Giuseppe Palermo, Emilio Sacco, Pier Francesco Bassi

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

In case of high grade non-muscle invasive bladder cancer (HG-NMIBC), intravesical BCG represents the first-line treatment; despite the “gold” standard therapy, up to 50% of patients relapse, needing radical cystectomy. Hence, alternative therapeutic strategies have been developed. The aim of the study was to evaluate a first-line salvage treatment with EMDA®-MMC in patients with HGNMIBC unresponsive to BCG.

Methods

We carried out a prospective, single-center, single-arm Phase II study in order to evaluate the efficacy (in terms of recurrence and progression) and the safety of the EMDA®-MMC treatment in 26 (21 male, 5 female) consecutive patients with “BCG refractory” HGNMIBC on a 3 years follow-up.
EMDA®-MMC treatment consisted of 40 mg of MMC diluted in 100 ml of sterile water retained in the bladder for 30 min with 20 mA pulsed electric current.
EMDA®-MMC regimen consisted of an induction course of 6 weekly instillations followed by a maintenance course of 6 monthly instillations.
Follow-up was performed with systematic mapping biopsies of the bladder (with sampling in the prostatic urethra for men), voiding and washing urinary cytology, radiological study of the upper urinary tract.
We performed Survival Kaplan-Meier curves and Log-rank test in order to analyze high grade disease-free survival.

Results

At the end of follow-up, 16 patients (61.5%) preserved their native bladder; 10 patients (38.4%) underwent radical cystectomy, in 6 patients (23.1%) for recurrent HGNMIBC and in 4 patients (15.4%) for progression to muscle-invasive disease.
At the end of follow-up, stratifying patients based on TNM classification (TaG3, T1G3, Cis, TaT1G3 + Cis), disease-free rates were 75, 71.4, 50 and 25%, respectively; survival curves showed statistically significant differences (p value < 0.05).
Regarding toxicity, we reported severe adverse systemic event of hypersensitivity to the MMC in 3 patients (11.5%), and local side effects in 6 patients (26.1%).

Conclusions

In the field of alternative strategies to radical cystectomy, the EMDA®-MMC could be considered safe and effective in high-risk NMIBC unresponsive to BCG, as a “bladder sparing” therapy in selected patients. Multicenter studies with a larger number of patients and a longer follow-up might confirm our preliminary results.

Trial registration

EudraCT2017-002585-43. 17 June 2017 (retrospectively registered).
Literature
1.
Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71(3):447–61.CrossRef
2.
Brausi M, Witjes JA, Lamm D, et al. A review of current guidelines and best practice recommendations for the management of non- muscle invasive bladder cancer by the international bladder Cancer group. J Urol. 2011;186:2158–67.CrossRefPubMed
3.
Böhle A, Brandau S. Immune mechanisms in bacillus Calmette–Guérin immunotherapy for superficial bladder cancer. J Urol. 2003;170(3):964–9.CrossRefPubMed
4.
Gontero P, Bohle A, Malmstrom PU, et al. The role of bacillus Calmette–Guérin in the treatment of non-muscle-invasive bladder cancer. Eur Urol. 2010;57(3):410–29.CrossRefPubMed
5.
Shelley MD, Mason MD, Kynaston H. Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat Rev. 2010;36(3):195–205.CrossRefPubMed
6.
Sylvester RJ, Brausi MA, Kirkels WJ, et al. Long-term efficacy results of EORTC Genito-Urinary Group randomized Phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette–Guérin, and bacillus Calmette– Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2009;57(5):766–73.CrossRefPubMedPubMedCentral
7.
Ojea A, Nogueira JL, Solsona E, et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette–Guérin (27 mg) versus very low-dose bacillus Calmette–Guérin (13.5 mg) versus mitomycin C. Eur Urol. 2007;52(5):1398–406.CrossRefPubMed
8.
Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666–75.CrossRefPubMed
9.
Herr HW. Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol. 1997;80:762–5.CrossRefPubMed
10.
Amling CL, Thrasher JB, Frazier HA, Dodge RK, Robertson JE, Paulson DF. Radical cystectomy for stages ta, tis and T1 transitional cell carcinoma of the bladder. J Urol. 1994;151(1):31–5.CrossRefPubMed
11.
Raj GV, Herr H, Serio AM, et al. Treatment paradigm shift may improve survival of patients with high risk supe 316 rficial bladder cancer. J Urol. 2007;177:1283–6.CrossRefPubMed
12.
Bianco FJ Jr, Justa D, Grignon DJ, Sakr WA, Pontes JE, Wood DP Jr. Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol. 2004;22:290–4.CrossRefPubMed
13.
Hautmann RE, Volkmer BG, Gust K. Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1, G3). World J Urol. 2009;27:347–51.CrossRefPubMed
14.
Kulkarni GS, Finelli A, Fleshner NE, Jewett MA, Lopushinsky SR, Alibhai SM. Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med. 2007;4:e284.CrossRefPubMedPubMedCentral
15.
Kulkarni GS, Alibhai SM, Finelli A, et al. Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. Cancer. 2009;115:5450–9.CrossRefPubMed
16.
Ku JH, Lerner SP. Strategies to prevent progression of high-risk bladder cancer at initial diagnosis. Curr Opin Urol. 2012;22(5):405–14.CrossRefPubMed
17.
Giannantoni A, Di Stasi SM, Chancellor MB, et al. New frontiers in intravesical therapies and drug delivery. Eur Urol. 2006;50(6):1183–93.CrossRefPubMed
18.
Di Stasi SM, Vespasiani G, Giannantoni A, et al. Electromotive delivery of mitomycin C into human bladder wall. Cancer Res. 1997;57(5):875–80.PubMed
19.
Di Stasi SM, Giannantoni A, Massoud R, et al. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. Cancer Res. 1999;59(19):4912–8.PubMed
20.
Brausi M, Campo B, Pizzocaro G, et al. Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative phase II study. Urology. 1998;51:506–9.CrossRefPubMed
21.
Di Stasi SM, Giannantoni A, Stephen RL, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol. 2003;170:777–82.CrossRefPubMed
22.
Di Gianfrancesco L, Racioppi M, Ragonese M, Palermo G, Lenci N, Sacco E, Bassi PF. ElectroMotive drug administration (EMDA) of mitomycin C as first line salvage therapy in high risk “BCG-failure” non muscle invasive bladder. cancer: 3 years followup outcomes. J Urol. 2018;199(Issue 4):e1115.CrossRef
23.
Solsona E, et al. The 3-month clinical response to intravesical 347 therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol. 2000;164:685.CrossRefPubMed
24.
Herr HW, et al. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol. 2003;169:1706.CrossRef
25.
Lerner SP, et al. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol. 2009;27:155.CrossRefPubMed
26.
27.
28.
Malmstrom PU, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non muscle-invasive bladder cancer. Eur Urol. 2009;56:247.CrossRefPubMed
29.
Shelley MD, et al. A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001;88:209.CrossRefPubMed
30.
Han RF, et al. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006;67:1216.CrossRefPubMed
31.
Shelley MD, et al. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004;93:485.CrossRefPubMed
32.
Bohle A, et al. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169:90.CrossRefPubMed
33.
Sylvester RJ, et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology. 2005;66:90.CrossRefPubMed
34.
Sobin LH, Gospodariwicz M, Wittekind C, editors. TNM classification of malignant tumors. UICC International Union Against Cancer. 7th ed: Wiley-Blackwell; 2009. p. 262–5. http://​www.​uicc.​org/​tnm/​
35.
Sauter G, Algaba F, Amin M, et al. Tumours of the urinary system: non-invasive urothelial neoplasias. In: Eble JN, Sauter G, Epstein J, Sesterhenn I, editors. WHO classification of classification of tumours of the urinary system and male genital organs. Lyon: IARCC Press; 2004. p. 29–34.
36.
Sockett LJ, Borwell J, Symes A, Parker T, Montgomery BSI, Barber NJ. Electro-motive drug administration (EMDA) of intravesical mitomycin-C in patients with high-risk non-invasive bladder cancer and failure of BCG immunotherapy. BJU Int. 2008;101(suppl 5):50 abs #U17.
37.
Nativ O, Witjes JA, Hendricksen K, et al. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette–Guérin. J Urol. 2009;182(4):1313–7.CrossRef
38.
39.
Riedl CR, Knoll M, Plas E, Pflüger H. Intravesical electromotive drug administration technique: preliminary results and side effects. J Urol. 1998;159(6):1851–6.CrossRefPubMed
Metadata
Title
ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes
Authors
Marco Racioppi
Luca Di Gianfrancesco
Mauro Ragonese
Giuseppe Palermo
Emilio Sacco
Pier Francesco Bassi
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-5134-7

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

HTLV-1-host interactions on the development of adult T cell leukemia/lymphoma: virus and host gene expressions

Correction

Correction to: Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy

Research article

NKX2.5 is expressed in papillary thyroid carcinomas and regulates differentiation in thyroid cells

Research article

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer

Research article

Genomic alterations in gastric cancers discovered via whole-exome sequencing

Research article

Radiosensitization of clioquinol and zinc in human cancer cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits